Mounjaro(Tirzepatide)
LLY
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Eli Lilly and Company
$6.33B
Medicare cost, 2024
$6.33B
Medicare cost, 2024
Medicare drug plans spent $6.3 billion on Mounjaro (tirzepatide) in 2024, for 5.1 million prescriptions and refills filled by 894,243 patients. It ranks 4th among all drugs by Medicare drug plan spending. Spending rose 168% from 2023 to 2024. It was first approved in 2022.
Medicare cost, 2024
$6.33B
+168.3% from 2023
Prescriptions
5.1M
$1,241.24 per claim
Patients
894K
194,653 prescribers
Total spending, 2024
$6.34B
$7,083.70 per patient
Questions and answers
How much does Medicare spend on Mounjaro?
Medicare prescription drug plans paid $6.33B for Mounjaro in 2024, for 5,103,556 prescriptions and refills to 894,243 patients (up 168.3% from 2023). The average cost per claim was $1,241.24.
Which state spends the most on Mounjaro?
Texas had the highest Medicare cost for Mounjaro in 2024: $624.0M for 491,789 claims, followed by Florida ($494.1M).
Who prescribes Mounjaro the most?
Shahed Quyyumi, endocrinology in Staten Island, NY, had the highest Medicare cost for Mounjaro in 2024: 1,709 claims costing $2.5M.
Who makes Mounjaro?
Mounjaro is made by Eli Lilly and Company (LLY), listed in the Medicare spending data as Eli Lilly & Co..
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Mounjaro was $6.34B in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Mounjaro, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Shahed Quyyumi Staten Island, NY | Endocrinology | 1,709 | 299 | $2.5M |
| Eugenio Angueira-Serrano Miami, FL | Endocrinology | 1,949 | 293 | $2.1M |
| Stella Ilyayeva Rego Park, NY | Internal Medicine | 1,720 | 316 | $2.0M |
| Chitharanjan Duvoor Jonesboro, AR | Endocrinology | 1,348 | 250 | $1.9M |
| Iraklii Buziashvili Brooklyn, NY | Endocrinology | 1,704 | 305 | $1.8M |
| Gary Reznik Los Angeles, CA | Cardiology | 1,751 | 214 | $1.8M |
| Anastasios Manessis New York, NY | Endocrinology | 1,281 | 256 | $1.7M |
| Muhammad I Choudhry Weatherford, TX | Endocrinology | 1,146 | 249 | $1.6M |
| Najmuddin K Karimjee Houston, TX | Internal Medicine | 1,199 | 271 | $1.6M |
| Matthew F Kamil Concord, NH | Endocrinology | 1,096 | 202 | $1.6M |
| Swarna Varma Pittsburgh, PA | Endocrinology | 1,268 | 189 | $1.5M |
| Mohammad T Ijaz Zanesville, OH | Endocrinology | 1,363 | 222 | $1.5M |
| Vita Anksh Naples, FL | Endocrinology | 1,206 | 203 | $1.5M |
| Kalyani Regeti North Port, FL | Endocrinology | 892 | 170 | $1.4M |
| Joseph Terrana Nesconset, NY | Endocrinology | 1,043 | 170 | $1.4M |
| Wael E Eid Covington, KY | Endocrinology | 1,084 | 212 | $1.4M |
| Amer Issa Saginaw, MI | Endocrinology | 1,089 | 219 | $1.4M |
| Matin Sharafatkhah Brooklyn, NY | Endocrinology | 1,331 | 196 | $1.4M |
| Benjamin D Prohaska Reno, NV | Physician Assistant | 960 | 169 | $1.4M |
| Rory S Breidbart New Hyde Park, NY | Endocrinology | 1,017 | 143 | $1.4M |
| Pamela Lopez Weslaco, TX | Nurse Practitioner | 881 | 193 | $1.4M |
| Carla L Hudson Opelika, AL | Nurse Practitioner | 1,141 | 192 | $1.3M |
| Monica G Robles Anniston, AL | Endocrinology | 850 | 188 | $1.3M |
| Robert M Oberstein Hartford, CT | Endocrinology | 986 | 148 | $1.3M |
| Leila Chaychi San Carlos, CA | Endocrinology | 957 | 167 | $1.3M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 30,007 | 121,050 | 54,187 | $144.0M |
| 2023 | 118,860 | 1,820,883 | 370,074 | $2.36B |
| 2024 | 194,653 | 5,103,556 | 894,243 | $6.33B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Eli Lilly & Co. | 5,105,397 | $6.34B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 25
- RxNorm concept IDs
- 2601743, 2601746, 2601755, 2601758, 2601761
- Application numbers
- NDA215866
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 181,068 side-effect reports named tirzepatide, the active ingredient of Mounjaro (reports from 2015 on). 33,098 of them (18.3%) were serious, 1,048 named a death and 11,889 named a hospital stay. The reactions named most often were incorrect dose administered, nausea and injection site pain. 180,951 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
181,068
62,324 in 2025 (+88.5% from 2024)
Serious
18.3%
33,098 reports
Deaths named
1,048
0.6% of reports
Hospital stays
11,889
6.6% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Mounjaro?
181,068 reports from 2015 through September 2026 named tirzepatide, the active ingredient of Mounjaro. 33,098 of them (18.3%) were serious, 1,048 named a death and 11,889 named a hospital stay.
What are the most reported side effects of Mounjaro?
32,155 reports named incorrect dose administered, the reaction named most often, followed by nausea (19,738) and injection site pain (14,616). In the last 5 years the reaction named most often was incorrect dose administered (32,150 reports). A report can name several reactions.
How many side-effect reports named Mounjaro in 2025?
62,324 reports were received in 2025 (+88.5% from 2024). 2026 so far: 59,716 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Mounjaro caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Mounjaro caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with tirzepatide: Zepbound
- Makers on the stock market:
LLY·LLY drug pipeline - Drug approvals (2 approvals on file for tirzepatide) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (tirzepatide) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.